PDCD1 and head and neck squamous cell carcinoma: In single-arm phase 1 and phase 2 trial, the MPR rate was reported as 60% and 63% when the combination of anti-PD-1 (toripalimab or camrelizumab) and chemotherapy (albumin paclitaxel and cisplatin) was administered in patients with locally advanced HNSCC.19